Carla van Tienen, Maarten Schim van der Loeff, Ingrid Peterson, Matthew Cotten, Sören Andersson, Birgitta Holmgren, Tim Vincent, Thushan de Silva, Sarah Rowland-Jones, Peter Aaby, Hilton Whittle
BACKGROUND: Survival of people with HIV-2 and HTLV-1 infection is better than that of HIV-1 infected people, but long-term follow-up data are rare. We compared mortality rates of HIV-1, HIV-2, and HTLV-1 infected subjects with those of retrovirus-uninfected people in a rural community in Guinea-Bissau.
METHODS: In 1990, 1997 and 2007, adult residents (aged ≥15 years) were interviewed, a blood sample was drawn and retroviral status was determined. An annual census was used to ascertain the vital status of all subjects. Cox regression analysis was used to estimate mortality hazard ratios (HR), comparing retrovirus-infected versus uninfected people.
RESULTS: A total of 5376 subjects were included; 197 with HIV-1, 424 with HIV-2 and 325 with HTLV-1 infection. The median follow-up time was 10.9 years (range 0.0-20.3). The crude mortality rates were 9.6 per 100 person-years of observation (95% confidence interval 7.1-12.9) for HIV-1, 4.1 (3.4-5.0) for HIV-2, 3.6 (2.9-4.6) for HTLV-1, and 1.6 (1.5-1.8) for retrovirus-negative subjects. The HR comparing the mortality rate of infected to that of uninfected subjects varied significantly with age. The adjusted HR for HIV-1 infection varied from 4.0 in the oldest age group (≥60 years) to 12.7 in the youngest (15-29 years). The HR for HIV-2 infection varied from 1.2 (oldest) to 9.1 (youngest), and for HTLV-1 infection from 1.2 (oldest) to 3.8 (youngest).
CONCLUSIONS: HTLV-1 infection is associated with significantly increased mortality. The mortality rate of HIV-2 infection, although lower than that of HIV-1 infection, is also increased, especially among young people.
J Acquir Immune Defic Syndr. 2008 Aug 15;48(5):607-10
[PMID:
18645510]
AIDS Res Hum Retroviruses. 2002 Nov 1;18(16):1167-73
[PMID:
12487822]
Retrovirology. 2007 Nov 27;4:85
[PMID:
18042276]
Retrovirology. 2004 Mar 24;1:4
[PMID:
15169553]
Am J Trop Med Hyg. 1993 Dec;49(6):664-71
[PMID:
8279633]
J Acquir Immune Defic Syndr. 2000 Oct 1;25(2):157-63
[PMID:
11103046]
AIDS. 1997 May;11(6):801-7
[PMID:
9143613]
J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Aug 15;15(5):381-6
[PMID:
9342259]
J Acquir Immune Defic Syndr. 2010 Apr;53(5):640-7
[PMID:
19841588]
AIDS Rev. 2009 Jan-Mar;11(1):8-16
[PMID:
19290030]
Retrovirology. 2010 May 19;7:46
[PMID:
20482865]
Lancet. 1997 Mar 29;349(9056):911-4
[PMID:
9093252]
J Acquir Immune Defic Syndr. 2005 Dec 15;40(5):625-8
[PMID:
16284541]
J Med Virol. 2004 Oct;74(2):207-15
[PMID:
15332268]
AIDS. 2001 Nov 23;15(17):2303-10
[PMID:
11698704]
J Acquir Immune Defic Syndr. 2002 Jul 1;30(3):342-50
[PMID:
12131572]
AIDS. 2003 Jul 4;17(10):1513-20
[PMID:
12824789]
AIDS. 1996 Nov;10(13):1585-90
[PMID:
8931796]
Int J Cancer. 1998 May 4;76(3):293-8
[PMID:
9579561]
AIDS. 2010 Mar 13;24(5):783-5
[PMID:
20215883]
Int J Infect Dis. 2010 Sep;14 Suppl 3:e142-7
[PMID:
20395161]
PLoS Med. 2007 Oct 16;4(10):e296
[PMID:
17941714]
Scand J Infect Dis. 1999;31(5):459-66
[PMID:
10576124]
Lancet Infect Dis. 2007 Apr;7(4):266-81
[PMID:
17376384]
J Infect Dis. 2003 Dec 1;188(11):1648-51
[PMID:
14639534]
J Neurol Neurosurg Psychiatry. 2009 Jan;80(1):66-8
[PMID:
18977823]
J Infect Dis. 1996 Jan;173(1):245-8
[PMID:
8537668]
AIDS. 2002 May 3;16(7):1059-66
[PMID:
11953473]
AIDS. 2002 Sep 6;16(13):1775-83
[PMID:
12218389]
J Med Virol. 2005 Jun;76(2):143-5
[PMID:
15834880]
AIDS. 2003 Jan 24;17(2):241-53
[PMID:
12545085]
PLoS Med. 2009 Apr 28;6(4):e1000066
[PMID:
19399157]
AIDS. 2009 Mar 13;23(5):637-9
[PMID:
19242315]
AIDS. 1994 Jul;8(7):977-82
[PMID:
7946109]
Jpn J Cancer Res. 1994 Mar;85(3):231-7
[PMID:
8188520]
Retrovirology. 2010 Jun 04;7:50
[PMID:
20525366]
